Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plantar fascia thickness in type 1 diabetes mellitus patients: Clinical associations and metabolic correlates.

Journal of diabetes investigation·2026
Same author

Branched-chain amino acids for people with cirrhosis and hepatic encephalopathy.

The Cochrane database of systematic reviews·2026
Same author

Expert Delphi Consensus on Surrogate Endpoints for Treatment Assessment in Metabolic Dysfunction-associated Steatohepatitis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2025
Same author

[The network of the EASY-NET programme: a contribution to knowledge on the effectiveness of audit&feedback].

Epidemiologia e prevenzione·2024
Same author

Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study.

JHEP reports : innovation in hepatology·2024
Same author

Breakthrough in the Treatment of Metabolic Associated Steatotic Liver Disease: Is it all over?

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2024

Related Experiment Video

Updated: Jun 28, 2026

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

Obesity-associated liver disease.

Giulio Marchesini1, Simona Moscatiello, Silvia Di Domizio

  • 1University of Bologna, Via Massarenti, 9, I-40138 Bologna, Italy. giulio.marchesini@unibo.it

The Journal of Clinical Endocrinology and Metabolism
|December 4, 2008
PubMed
Summary

Obesity significantly elevates the risk of liver disease, including nonalcoholic fatty liver disease and its progression. Addressing obesity through lifestyle changes and public policy is crucial for managing this growing health concern.

More Related Videos

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
07:03

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease

Published on: July 19, 2024

Related Experiment Videos

Last Updated: Jun 28, 2026

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
07:03

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease

Published on: July 19, 2024

Area of Science:

  • Hepatology
  • Public Health
  • Metabolic Syndrome

Background:

  • Accumulating evidence links obesity to increased liver disease risk and progression.
  • The global obesity epidemic poses a significant threat to public health, contributing to morbidity and mortality.
  • Obesity is increasingly recognized as a major driver of liver pathology.

Purpose of the Study:

  • To review the evidence linking obesity to liver disease risk in the general population.
  • To examine obesity as a risk factor for nonalcoholic fatty liver disease (NAFLD) and its progression.
  • To synthesize current knowledge on the association between obesity and liver health.

Main Methods:

  • Literature review focusing on obesity and liver disease.
  • Analysis of epidemiological data on obesity and liver enzyme elevation.
  • Examination of ultrasonography findings in overweight and obese individuals.
  • Review of studies on obesity's role in cirrhosis and hepatocellular carcinoma.
  • Assessment of obesity and weight gain in relation to fibrosis progression in NAFLD patients.

Main Results:

  • Obesity increases the risk of elevated liver enzymes 2-3 fold.
  • Overweight and obesity are associated with increased risk of hepatic steatosis, with risk peaking at 15-fold in obesity.
  • Obesity is linked to cirrhosis and hepatocellular carcinoma in the general population.
  • In NAFLD patients, obesity and weight gain correlate with advanced fibrosis and accelerated fibrosis progression.

Conclusions:

  • Metabolic liver disease associated with obesity is the most common liver disease in Western countries.
  • Behavioral programs promoting healthier lifestyles are essential for managing obesity-associated liver disease.
  • Public health policies are necessary to support societal-level lifestyle changes and combat obesity-related liver disease.